In last trading session, Applied Therapeutics Inc (NASDAQ:APLT) saw 1.83 million shares changing hands with its beta currently measuring 1.99. Company’s recent per share price level of $0.44 trading at -$0.02 or -4.15% at ring of the bell on the day assigns it a market valuation of $51.32M. That closing price of APLT’s stock is at a discount of -2313.64% from its 52-week high price of $10.62 and is indicating a premium of 2.27% from its 52-week low price of $0.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.56 million shares which gives us an average trading volume of 3.51 million if we extend that period to 3-months.

For Applied Therapeutics Inc (APLT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.18 in the current quarter.

Applied Therapeutics Inc (NASDAQ:APLT) trade information

Upright in the red during last session for losing -4.15%, in the last five days APLT remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $0.44 price level, adding 21.4% to its value on the day. Applied Therapeutics Inc’s shares saw a change of -48.49% in year-to-date performance and have moved -15.73% in past 5-day. Applied Therapeutics Inc (NASDAQ:APLT) showed a performance of -8.51% in past 30-days. Number of shares sold short was 18.2 million shares which calculate 7.31 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 4.5 to the stock, which implies a rise of 90.22% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -809.09% in reaching the projected high whereas dropping to the targeted low would mean a loss of -809.09% for stock’s current value.

Applied Therapeutics Inc (APLT) estimates and forecasts

This year revenue growth is estimated to fall -94.47% from the last financial year’s standing.

3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 100k for the same. And 3 analysts are in estimates of company making revenue of 12.32M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -8.72% during past 5 years.

Applied Therapeutics Inc (NASDAQ:APLT)’s Major holders

Insiders are in possession of 6.47% of company’s total shares while institution are holding 107.37 percent of that, with stock having share float percentage of 114.80%. Investors also watch the number of corporate investors in a company very closely, which is 107.37% institutions for Applied Therapeutics Inc that are currently holding shares of the company. FRANKLIN RESOURCES INC is the top institutional holder at APLT for having 10.21 million shares of worth $47.69 million. And as of 2024-06-30, it was holding 70.7533 of the company’s outstanding shares.

The second largest institutional holder is VR ADVISER, LLC, which was holding about 9.54 million shares on 2024-06-30. The number of shares represents firm’s hold over 66.1112 of outstanding shares, having a total worth of $44.57 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Small-Cap Value Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.1 shares of worth $1.37 million or 2.67% of the total outstanding shares. The later fund manager was in possession of 3.04 shares on Dec 31, 2024 , making its stake of worth around $1.34 million in the company or a holder of 2.61% of company’s stock.